Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-05-28
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotechnology company using a proprietary AI, data, and automated lab stack to discover drugs internally and with pharmaceutical partners.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical proof sets the next rerating
The stock looks inexpensive because the market still wants proof, not more AI narrative. A clear path for the lead rare-disease program and steadier platform monetization could lift the business into a higher-quality biotech valuation band by 2031.

Analysis

Thesis
Recursion can benefit from the AI era because its scarce asset is not generic software but a closed loop of proprietary data, automated experiments, and owned drug programs; if the lead rare-disease asset earns a clear late-stage path and partner economics shift toward milestones and royalties, the stock can rerate from concept status to a higher-quality product-plus-platform biotech by 2031.
Last Economy Alignment
Cheaper cognition helps Recursion because value sits in proprietary experiment data, wet-lab throughput, and downstream asset economics rather than seat pricing; the main limiter is clinical proof, not software commoditization.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.3x (from 5 most recent analyses)
Reasoning
The upside is a quality shift, not just more discovery activity. If one owned program gains a credible late-stage path, a second internal program stays viable, and new deals keep more downstream economics, investors can value the business as a hybrid drug creator and discovery platform instead of a cash-burning research service. That supports a realistic path to low-20s annualized equity compounding rather than an extreme moonshot.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not lack of AI capability; it is failure to turn faster discovery into repeatable human proof. If the lead rare-disease asset does not get a clear late-stage path, early oncology programs stay inconclusive, or partner milestones remain sporadic, Recursion can remain a cash-backed option story with periodic dilution instead of compounding into a higher-quality biotech business.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.41
They own a data-and-lab machine that gets more useful as AI gets cheaper, so better models should help them find and improve drug ideas faster. The catch is that biology and regulators, not software, still decide whether that advantage becomes real money.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$6.64
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case